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Abstract
Objective
We used patient-speciﬁc neuronal cultures to characterize the molecular genetic mechanism of
recessive nonsense mutations in neuroﬁlament light (NEFL) underlying early-onset Charcot-
Marie-Tooth (CMT) disease.
Methods
Motor neurons were diﬀerentiated from induced pluripotent stem cells of a patient with early-
onset CMT carrying a novel homozygous nonsense mutation in NEFL. Quantitative PCR,
protein analytics, immunocytochemistry, electron microscopy, and single-cell transcriptomics
were used to investigate patient and control neurons.
Results
We show that the recessive nonsense mutation causes a nearly total loss of NEFL messenger
RNA (mRNA), leading to the complete absence of NEFL protein in patient’s cultured neurons.
Yet the cultured neurons were able to diﬀerentiate and form neuronal networks and neuro-
ﬁlaments. Single-neuron gene expression ﬁngerprinting pinpointed NEFL as the most down-
regulated gene in the patient neurons and provided data of intermediate ﬁlament transcript
abundancy and dynamics in cultured neurons. Blocking of nonsense-mediated decay partially
rescued the loss of NEFL mRNA.
Conclusions
The strict neuronal speciﬁcity of neuroﬁlament has hindered the mechanistic studies of re-
cessive NEFL nonsense mutations. Here, we show that such mutation leads to the absence of
NEFL, causing childhood-onset neuropathy through a loss-of-function mechanism. We pro-
pose that the neuroﬁlament accumulation, a common feature of many neurodegenerative
diseases, mimics the absence of NEFL seen in recessive CMT if aggregation prevents the proper
localization of wild-type NEFL in neurons. Our results suggest that the removal of NEFL as
a proposed treatment option is harmful in humans.
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Neuroﬁlaments are 10-nm-wide intermediate ﬁlaments ex-
clusive to neurons and crucial for the maintenance of neu-
rite structure and integrity.1 Neuroﬁlament light chain
(NEFL) is among the core subunits of neuroﬁlament,
usually forming heterodimers with medium (NEFM) and
heavy chains (NEFH), sometimes supplemented with ei-
ther α-internexin (INA) or peripherin (PRPH). The toxic
accumulation of neuroﬁlament is a hallmark of many neu-
rodegenerative disorders,2–4 and thus, the removal of NEFL
has been investigated as a treatment option.5 In addition,
the potential of NEFL as a serum biomarker of neuronal
injury in a number of neurologic disorders is currently
investigated.6–9
Genemutations inNEFL have been found to underlie Charcot-
Marie-Tooth disease (CMT), either the demyelinating
CMT1F4 or axonal CMT2E10 form.10,11 Most disease-causing
NEFL mutations are dominantly inherited missense variants
functioning through a gain-of-function mechanism,12,13 in
which the missense mutant NEFL protein disrupts neuroﬁla-
ment assembly and organelle transport in the axons by forming
aggregates.14,15 All reported recessive NEFL mutations have
been homozygous nonsense variants.13,16,17 Elucidation of the
diseasemechanism of the recessive variants in humans has been
complicated by the restricted neuronal expression of NEFL.18
Thus, it is not known if the homozygous nonsense variants
cause disease through aggregation eﬀects mediated by a trun-
cated protein or by the loss of NEFL protein through
nonsense-mediated messenger RNA (mRNA) decay (NMD).
Here, we used patient-speciﬁc induced pluripotent stem cell
(iPSC)-derived neuronal cultures and report that the complete
absence of NEFL in patients with a homozygous NEFL non-
sense mutation causes early-onset CMT.
Methods
Standard protocol approvals, registrations,
and patient consents
Patient and control samples were taken according to the
Declaration of Helsinki, with informed consent. The study
was approved by the Institutional Review Board of the Hel-
sinki University Hospital.
Patients
Two siblings, patients P1 and P2, now aged 30 and 27 years,
respectively, who were born to healthy unrelated parents of
Finnish origin, were investigated for motor and de-
velopmental delay in early childhood. The skin ﬁbroblasts
used in the study were derived from patient P1. Experimental
details are described in the e-Methods (appendix e-1, link-
s.lww.com/NXG/A54).
Results
Clinical findings
P1 was ﬁrst examined as an infant because of nystagmus and
tremor. Her feet were deformed resembling clubfoot, and
her movements were clumsy. She learned to walk at the age
of 20 months. Electrophysiology showed strongly de-
creased nerve conduction velocities (NCVs) corresponding
to demyelinating sensorimotor neuropathy. At the age of 8
years, there was no response from the sensory median
nerve. Ulnar sensory NCVs from the wrist to ﬁnger and the
elbow to wrist were 9 and 19 m/s, respectively. Median and
ulnar motor NCVs from the elbow to wrist were 21 and 16
m/s, respectively. The only response in the lower leg was
recorded from tibialis anterior. Four years later, sensory
NCVs were absent in all upper limb nerves (ie, radial, ulnar,
and median). Median motor response was also absent, and
ulnar NCVs were markedly reduced (ie, 11 m/s from the
elbow to wrist, no response from the wrist to ﬁnger).
Needle examination showed denervation. There were un-
speciﬁc mild white matter lesions on her brain MRI that
were not progressive. Her younger brother, P2, had similar
symptoms and electrophysiologic ﬁndings, although less
severe, and his brain MRI was normal. During their school
years, the patients were estimated to be approximately 2
years behind their peers in cognitive development. How-
ever, both managed to ﬁnish supported elementary school
despite diﬃculties.
As neuropathy slowly progressed, distal muscle weakness
became apparent in upper and lower extremities. Muscle at-
rophy was evident in the legs and intrinsic hand muscles. Both
patients underwent orthopedic surgery for feet deformities
and tight Achilles tendon. Distal weakness and waddling gait
were observed. P2, aged 27 years, can still walk 50 m without
aid, whereas P1 lost ambulation at the age of 25 years. For
both patients, grip strength was reduced, pinching impossible,
and ﬁne motor skills decreased. Weakness in ﬁnger extension
and ﬂexion was severe (1-2/5 Medical Research Council
[MRC] scale). All movements were essentially lost in ankle
plantar and dorsiﬂexion. There was also proximal muscle
weakness in the upper and lower limbs but to a lesser extent
(3-4/5 MRC). Tendon reﬂexes were absent. No clear sensory
disturbances were found. In both patients, articulation was
slow, but there were no dysarthria, facial weakness, or other
bulbar symptoms.
Glossary
CMT = Charcot-Marie-Tooth; INA = internexin; iPSC = induced pluripotent stem cell; mRNA = messenger RNA; NCV =
nerve conduction velocity; NEFH = neuroﬁlament heavy; NEFL = neuroﬁlament light; NEFM = neuroﬁlament medium;
NMD = nonsense-mediated mRNA decay; PRPH = peripherin; qPCR = quantitative PCR;UMI = unique molecular identiﬁer.
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P1 was also diagnosed with ventricle septum defect in child-
hood and later aortic valve stenosis and regurgitation, sleep
apnea, and severe obesity. The parents were healthy; both
underwent electrophysiologic studies as part of their child-
ren’s investigations with normal NCVs.
Genetic findings
Targeted next-generation sequencing panel for known
CMT disease genes19 for the DNA sample of P1 revealed
a novel homozygous c.1099C>T (g.24811765C>T) variant
in exon 2 of the NEFL gene, predicting a nonsense change
p.Arg367*. The patients were homozygous for the variant,
and parents were heterozygous carriers (ﬁgure 1A). The
GnomAD20 database (277,044 alleles) lists 15 heterozygous
carriers of the variant in Finland, indicating an enrichment of
the variant with a carrier frequency of 0.00058. The locali-
zation of the variant together with previously reported
disease-causing variants in NEFL domains is summarized in
ﬁgure 1B.
Absence of NEFL in patient-specific
cultured neurons
To investigate the consequences of the NEFL nonsense var-
iant, we diﬀerentiated patient-speciﬁc iPSC, reprogrammed
from P1 skin ﬁbroblasts, into neurons. Two iPSC clones were
used from P1, and 1 clone each from 3 unrelated control
iPSCs. We used the motor neuron diﬀerentiation protocol,
modiﬁed from reference 21 as summarized in ﬁgure 2A. We
veriﬁed the neuronal diﬀerentiation by quantitative PCR
(qPCR) of microtubule-associated protein 2 (MAP2) and
βIII-tubulin (TUBB3) mRNA expression (ﬁgure 2B) and by
immunocytochemistry with TUBB3 (TUJ1) and MAP2
antibodies (ﬁgure 2C). Approximately 90% of DAPI-positive
cells were also MAP2 and/or TUJ1 positive in each imaged
frame. To validate the motor neuronal identity of the diﬀer-
entiated neurons, we analyzed the expression levels of ISL
LIM homeobox 1 (ISL1), motor neuron and pancreas
homeobox 1 (MNX1), and acetylcholine transferase (CHAT)
by qPCR (ﬁgure 2D). Although some variation was detected
Figure 1 Dominant and recessive missense and nonsense variants in neurofilament light (NEFL)
(A) Sequencing traces of the c.1099C>T variant in the family members show that both parents of the patients are heterozygous carriers of the mutation. (B)
NEFL protein domains are depicted, and the localization of the reported missense and nonsense variants is indicated (modified from references 17 and 25).
The nonsense variant A367* identified in this study is shown in red.
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Figure 2 Neuron differentiation and validation
(A)Work-flowof fibroblast-derived inducedpluripotent stemcell (iPSC) differentiation intomotor neurons;Wnt signaling pathway activator (WNTact), retinoic
acid (RA), Sonic hedgehog (SHH), growth factors (GF; BDNF, IGF-1 andCNTF), Poly-D-lysine (PDL). (B) Validation of the expression of neural transcriptsMAP2 and
TUBB3 against GAPDH by quantitative PCR (qPCR) in total culture RNA of patient 1 clones 1 (Pt C1) and 2 (Pt C2) and controls 1-3 (ctr 1-3) after motor neuron
differentiation. (C) Immunocytochemical analysis of MAP2 (green) and TUBB3 (red) proteins in patient 1 and control neuronal cultures. (D) Validation of the
expression of motor neural transcripts ISL1, MNX1, and CHAT by qPCR as in B. (E) Immunocytochemical analysis of ISL1 (red) and NEFM (green) protein in
patient 1 and control neuronal cultures. ISL1-positive neurons are shown in larger cell clusters in the final differentiation stage (day 14 of in PDL + laminin-
coated plates). (F) Expression of intermediate filament subunits neurofilament medium (NEFM), neurofilament heavy (NEFH), and neurofilament light (NEFL)
by qPCR as in B. The bars in each graph representmean levels ± SD, n = 3 for each cell line. All scale bars 50μm. 49,6-diamidino-2-phenylindole (DAPI) indicates
nuclear staining.
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between the diﬀerent clones for the motor neuron markers,
no decrease in diﬀerentiation potential was observed in pa-
tient lines in comparison with control lines. ISL1 expression
was conﬁrmed by immunocytochemistry in the neuronal
cultures (ﬁgure 2E).
We then analyzed the mRNA levels of NEFL, NEFM, and
NEFH and observed that the patient neuronal cultures had
a markedly decreased NEFL mRNA, with a residual level of
about 5% in patient vs control samples, whereas patient
NEFM and NEFH mRNA levels were comparable with con-
trol levels (ﬁgure 2F). This suggested that the nonsense
mutant NEFL transcript was degraded by NMD. We next
investigated whether NEFL protein could be detected in pa-
tient neurons by immunoblotting or immunocytochemistry.
Relatively, even neuronal diﬀerentiation of lysed samples was
validated by immunoblotting for TUJ1, NEFM, and CHAT
proteins (ﬁgure 3A). The NEFL nonsense variant had pre-
dicted a potential C-terminally truncated protein of 366
amino acids (approximately 45 kDa). However, the Western
blots of patient neuron lysates showed no full-length NEFL
polypeptide (68 kDa) or signs of a truncated NEFL protein
using either an N-terminal monoclonal (recognizing residues
6–25) or a polyclonal pan-NEFL antibody (ﬁgure 3A), in-
dicating that patient neurons were absent of NEFL. Using
immunocytochemistry, highly similar neurite structures and
neuronal networks were seen in patient and control motor
neurons by NEFM immunostaining (ﬁgure 3B). The patient
neurons did not show any staining with NEFL antibody,
conﬁrming that they were devoid of NEFL. However, they
were still able to form as long, branching projections as the
control neurons, suggesting that the intermediate ﬁlament
network in the absence of NEFL was suﬃcient for axonal
maintenance in culture.
Intermediate filament transcript dynamics in
cultured neurons
To examine the gene expression ﬁngerprints in single cultured
neurons, we used the diﬀerentiated neuronal cultures of P1
clone 1 and control 1 for single-cell transcriptomics by the
Macosko22 method with 10X Genomics Single Cell Plat-
form.23 After quality control, 1,336 cells could be proﬁled
from P1 clone 1 and 418 cells from control 1. The expression
of 17,318 genes could be reliably detected in these cells.
Clustering of the individual cells based on their transcriptome
proﬁles resulted in 5 clusters. Neuronal cells clustered dis-
tinctly from other cells, driven by the expression of neuron-
speciﬁc transcripts (ﬁgure 4A). Clustering revealed that 26.1%
of the captured cells from P1 clone 1 (349 of 1,336 cells) and
23.0% from control 1 (96 of 418 cells) had a neural identity,
depicted in t-SNE projections colored by the expression of
MAP2, microtubule-associated protein tau (MAPT), growth-
associated protein 43 (GAP43), and synaptophysin (SYP)
(ﬁgure 4B). The captured neurons also expressed motor
neuronal markers as depicted in ﬁgure 4C in which CHAT,
SLC18A3, ISL1,MNX1, LHX1, LHX3,DCC,ONECUT1, and
Figure 3 Complete loss of neurofilament light (NEFL) protein in cultured patient neurons
(A) Immunoblotting of whole cell lysates of patient 1 clones 1 and 2 (Pt C1 and C2) and controls 1-3 (ctr 1-3) after motor neuronal differentiation with an N-
terminal monoclonal or a polyclonal pan-NEFL antibody. Protein levels of neuronal markers ChAT, TUJ1, and neurofilament medium (NEFM) and the loading
control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as well as the stain-free blot are shown. (B) Immunocytochemical analysis of NEFM (green) and
NEFL (orange) of neurite architecture in patient 1 and control neurons after motor neural differentiation. 49,6-diamidino-2-phenylindole (DAPI) indicates
nuclear staining. Scale bars 50 μm.
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Figure 4 Transcriptome dynamics of patient and control neurons
(A) Clustering of the single cells derived from patient 1 and control iPSCs in the tSNE-plot based on their gene expression fingerprints. Different clusters are color
coded. In the combined single-cell sequencingdata, patient cells are shownas filleddots and control cells asdiamonds.Neurons are clusteredasa clearly separate
group of cells (cluster 1, red). (B)MAP2, MAPT, SYP, andGAP43 expression is high in the neuronal cluster cells. Red indicates high expression, and gray indicates low.
(C) Cells in the neural cluster express motor neuron lineage-specific transcripts, CHAT, SLC18A3, ISL1,MNX1, LHX1, LHX3, DCC, ONECUT1, and ONECUT2, summed in
the tSNE-plot. Purple indicates high expression, and gray indicates low. (D) Themost significantly upregulated and downregulated transcripts (adjusted p < 0.001
and absolute fold change ≥1.5) in the neural cluster between patient and control cells. Neurofilament light (NEFL) is the most downregulated transcript in the
patient neurons. (E) In the violin plots, each individual cell is shown with its specific transcript level, depicting the most downregulated transcript NEFL in patient
neurons, and evenly expressed intermediate filament subunit transcripts INA,NEFM,NEFH, PRPH, and VIM. Expression refers to normalized log(e) expression scale.
(F) Expression of NEFL against GAPDH by qPCR from total culture RNA of patient clones 1 (Pt C1) and 2 (Pt C2) and controls 1-3 (Ctr 1-3) after motor neuronal
differentiation, nontreated (NT) or treatedwith 200 μg/mL cycloheximide (CHX) for 18 hours. The comparisons weremade individually between each cell line with
and without CHX treatment, n = 3 for each cell line and treatment (unpaired 2-tailed t test, **p < 0.001, *p < 0.01). Bars represent mean levels ± SD.
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ONECUT2 are summed, indicating that these neurons are
part of the motor neuronal lineage. The neuronal diﬀer-
entiation eﬃciency in cultures was much greater than the
percentage of captured neurons, which reﬂects the diﬃculty
to capture neuronal cells with long extensions in contrast to
morphologically more favorable cell types. However, large
numbers of neurons were successfully captured from pa-
tient and control cultures, and the proportion of neuronal
cells of all captured cells was comparable in patient and
control data.
To gain an overall appreciation of the abundancy of the cap-
tured mRNAs per gene in the cultured neurons and of the
ratios of the diﬀerent intermediate ﬁlament transcripts, we
analyzed the mean unique molecular identiﬁer (UMI) counts
for each gene in the control neuronal cell cluster. The most
highly expressed gene was MALAT1 (metastasis associated
lung adenocarcinoma transcript 1), followed by a number of
genes for cytoskeletal proteins such as tubulin and actin, ri-
bosome subunits, and mitochondrial-DNA encoded oxidative
phosphorylation complex subunits (ﬁgure e-1, links.lww.com/
NXG/A51).NEFMwas the most highly captured intermediate
ﬁlament transcript (46th in abundance), closely followed by
NEFL (66th), whereas INA (238), VIM (2,728), PRPH
(2,991), and NEFH (3,456) were much less frequent (ﬁgure
e-1). The UMI counts per gene thus indicated that bothNEFL
and NEFM were very highly expressed transcripts in control
cultured neurons.
At a single-cell level, when comparing the autosomal tran-
script levels in the patient neurons with control neurons
(adjusted p < 0.001 and absolute fold change ≥1.5),NEFLwas
the most signiﬁcantly downregulated transcript (10-fold) in
the patient neurons (ﬁgure 4D). Violin plots in ﬁgure 4E
demonstrate the reduced level of NEFL transcripts in in-
dividual neurons of patient identity in comparison to control
identity, whereas other intermediate ﬁlaments were not sig-
niﬁcantly altered, indicating no transcriptional compensation.
Although we found no evidence of stable NEFL protein in
cultured patient neurons, the violin plot in ﬁgure 4E shows
that some neurons still expressed a low level ofNEFLmRNA.
To study NEFL transcript dynamics, we blocked NMD by
treating the neuronal cultures with cycloheximide (CHX), an
inhibitor of protein synthesis. CHX signiﬁcantly increased the
amount of nonsense NEFL mRNA in patient neuronal cul-
tures, but at the same time, CHX dramatically decreased the
amount of wild-type NEFLmRNA in control neurons (ﬁgure
4F). These results indicated that NMD machinery was re-
sponsible for the nonsense mRNA degradation but could not
completely abolish it because of its high abundancy. In ad-
dition, the NEFL mRNA levels appear to be tightly regulated
in relation to protein synthesis.
In this study, we did not investigate in detail the potential
other transcriptional alterations that were associated with
NEFL loss in patient’s cultured neurons, as these ﬁndings
require substantial additional studies. For example, urotensin
2 (UTS2), a small cyclic peptide shown previously to regulate
intracellular calcium in rat spinal cord neurons,24 was themost
upregulated gene in patient vs control neurons, but its ex-
pression proﬁle showed high variation within the individual
patient neurons (ﬁgure e-2, links.lww.com/NXG/A52).
Therefore, its speciﬁc role in association with NEFL loss is not
clear.
Neurite architecture
BecauseNEFL is believed to be a fundamental building block in
the intermediate ﬁlament network of axons and dendrites,1 we
examined neurites in our cultures. By immunocytochemistry,
we did not detect defects in neurite morphology in the patient’s
cultured neurons in comparison with control neurites. The
neurite signals for TUJ1, MAP2, and NEFM were not reduced
in patient cell lines (ﬁgure e-3A, links.lww.com/NXG/A53).
We also performed electron microscopic analysis to further
examine neurite structure.Neurite areas varied in cross sections,
from 7,000 to 170,000 nm2, but did not signiﬁcantly diﬀer
between control and patient samples (ﬁgure e-3B). Un-
expectedly, cross sections of patient neurites showed in addition
to microtubules a clear presence of intermediate ﬁlaments
(ﬁgure 5).We counted the percentages of neurite cross sections
that contained microtubules or ﬁlament bundles and observed
similar numbers in control and patient samples (ﬁgure e-3C).
Furthermore, the longitudinal sections of patient neurites dis-
played no signs of neuroﬁlament accumulation or abnormalities
indicating dysregulation in the microtubule network or axonal
transport. Collectively, these results showed that cultured hu-
man neurons can form neuroﬁlaments and maintain axonal
structure in the absence of NEFL.
Discussion
We describe here CMT1F patients with a novel homozygous
nonsense mutation in NEFL, and demonstrate that the mu-
tation leads to the absence of NEFL in patient-derived cul-
tured neurons. Both patients had the disease onset at infancy
and presented with severely reduced NCVs and slowly pro-
gressive distal muscle weakness in lower and upper extremi-
ties. The low NCVs suggested that myelin was lost in the
peripheral neurons, but nerve biopsies were not available from
the patients to investigate whether the reduced NCVs were
due to the dramatic loss of axonal caliber in the absence of
NEFL or the loss of myelin. Intermediate to severe reduction
in NCVs has been previously reported in association with
certain NEFL mutations.4,11 In addition to peripheral nerve
involvement, both of our patients had mild intellectual dis-
ability possibly also resulting from the NEFL defect, since
abnormalities in cognitive development have been previously
reported in a few patients with dominant or recessive NEFL
mutations.13,25
Recessively inherited NEFL nonsense mutations typically
cause an early-onset CMT.13,16,17 Homozygous p.Glu140*
mutation was described in 1 patient with gait disturbance and
progressive muscle weakness since school age,16 p.Glu210* in
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4 siblings with slowly progressive distal muscle weakness and
atrophy starting at approximately 1.5 years,13 and p.Glu163*
in an adolescent girl with muscle weakness and gait disturbances
during the ﬁrst decade.17 Although neuroﬁlament aggregation is
well documented for dominant NEFL mutations,12,13,26 as well
as in other neurodegenerative disorders,2,3 the molecular con-
sequences of recessive nonsense mutations in NEFL have not
been fully investigated. Neuronal speciﬁcity of NEFL has pre-
viously prevented studying the nonsensemutations in detail, and
especially in cells with endogenous levels of mutant NEFL
mRNA. Using neurons diﬀerentiated from patient-speciﬁc iPSC,
we unexpectedly observed that the recessive NEFL nonsense
mutation led to a complete absence of NEFL protein, through
NMD of the nonsense mutant mRNA.
In this study, we demonstrate the loss of NEFL mRNA and
protein in human neurons. In the literature, NEFL is largely
considered as an essential component of neuroﬁlament inmature
neurons together with NEFM andNEFH.15 The composition of
neuroﬁlaments is also dependent on the neuronal type and de-
velopmental stage.15 Our single-neuron transcriptomics showed
that NEFL and NEFM were highly abundant transcripts in the
cultured neurons, whereasNEFHwas not. LowNEFH transcript
capture is consistent with its expression increasing only as a result
of axonal maturation concomitant with myelination.27 INA and
PRPH may also contribute to neuroﬁlament formation, but are
mostly expressed during early embryonic neuronal diﬀerentia-
tion or in early postnatal brain, respectively,28,29 or following
neuronal injury.30,31 In the cultured neurons of this study, we
found the intermediate ﬁlaments expressed in the following or-
der of abundance: NEFM>NEFL>INA>VIM>NEFH>PRPH.
In the patient neurons lacking NEFL, we found no indication of
transcriptional compensation of other neuroﬁlament poly-
peptides, althoughwe could detect neuroﬁlaments in the neurites
by electron microscopy. This suggests that the intermediate ﬁl-
ament formation in cultured neurons does not require NEFL.
However, a recent study reported that a CMT patient with
recessive NEFL nonsense mutations had no neuroﬁlament in
axons in a nerve biopsy as detected by electron microscopy.17
Combined with our demonstration of NEFL nonsense muta-
tions leading to NEFL absence, their result indicates that in
human peripheral axons, the lack of NEFL protein indeed leads
to neuroﬁlament loss. It is possible that the transport of neuro-
ﬁlaments to the long distal sural nerve may be impaired in
patients, and this cannot be reproduced by the current in vitro
model. It is important that the attempts to remove NEFL as
a therapeutic intervention to its toxic accumulation5 should take
into account that its loss is equally harmful to peripheral neurons
and caused a severe early-onset disease in our patients. It is also
noteworthy that the full Neﬂ mouse knockout only displayed
a phenotype following nerve injury,32 suggesting major diﬀer-
ences in the neuroﬁlament biology between humans and mice,
which may be connected to axon length.
Previous study of iPSC-derived neurons from CMT indi-
viduals carrying a NEFL missense variant found NEFL
Figure 5 Neurite structure is not disrupted by the lack of neurofilament light (NEFL)
Representative electron microscopy images of
neurite architecture in patient 1 and control neu-
rons. Intermediate filaments (outlined arrow) and
microtubules (filled arrow) are indicated in cross
sections. Normal neurofilament network is seen in
longitudinal sections of patient neurites. Scale bars
500 nm.
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aggregate retention in the perikarya of neurons, possibly
disrupting the neuroﬁlament network and axonal mainte-
nance.33 Our results indicate that CMT can be caused by
both the loss of NEFL and its toxic accumulation.12 We
therefore speculate that in the cases of NEFL accumulation,
the toxicity is at least partly caused by the aggregates pre-
venting the proper localization and function of wild-type
NEFL, as well as disrupting the maintenance and turnover of
intermediate ﬁlaments in the axon. This could result in
NEFL loss in critical parts of the axons, similar to the situ-
ation in patients with recessive NEFL nonsense mutations.
Indeed, reduced neuroﬁlament has been detected in cuta-
neous nerve ﬁbers of patients with dominant CMT2E,
suggesting that aggregates in cell bodies led to neuroﬁlament
disruption distally.34
Here, we demonstrated that the absence of NEFL in human
neurons causes early-onset CMT. As a limitation of our study,
skin ﬁbroblasts of only 1 patient from the family were available
for iPSC generation. The lack of an obvious defect in neu-
roﬁlament formation in cultured patient-speciﬁc neurons
challenges the use of the current model system in studies of
pathogenic mechanisms. In addition, we presented a case in
which single-neuron transcriptomics could be used to identify
the genetic defect based on the consequent gene expression
alteration.
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